Technology Week Liechtenstein
SEE OTHER BRANDS

Hottest science and technology news from Liechtenstein

Latest News

Read the latest news from regional and global sources, presenting different voices and perspectives.

Zemcelpro Stem Cell Therapy Granted EC Conditional Marketing Authorizaion

Zemcelpro Stem Cell Therapy Granted EC Conditional Marketing Authorizaion

Montreal, Canada-based ExCellThera, a company specializing in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics, announced on Aug. 27, 2025 that it has received conditional marketing authorization by...

Gilead Sciences' twice─yearly injectable HIV─1 capsid inhibitor, Yeytuo receives European marketing authorization

Gilead Sciences, Inc., a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the European Commission (EC) has granted marketing authorization for Yeytuo (lenacapavir)—the...

Gilead Sciences gets European Commission marketing authorization for twice yearly Yeytuo for HIV prevention

Gilead Sciences gets European Commission marketing authorization for twice yearly Yeytuo for HIV prevention

Foster City: Gilead Sciences, Inc. has received the European Commission (EC) marketing authorization for Yeytuo (lenacapavir)-the company's twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the...

Gilead Sciences’ HIV PrEP Injectable Approved by European Commission

Gilead Sciences’ HIV PrEP Injectable Approved by European Commission

The European Commission (EC) has granted marketing authorization for lenacapavir, marketed by Gilead Sciences (Gilead) as Yeytuo, as a twice-yearly, injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor for pre-exposure prophylaxis...

Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win

Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win

Gilead Sciences (GILD) won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo. The approval comes two months after the Food and Drug Administration signed off on Yeztugo, the drug's branded name in the U.S....

Take Control of Your Cash Flow: Proven Strategies for AR Leaders

Thank you for your interest in the webinar! Check your inbox for an email with instructions on viewing this on-demand presentation. Oops something went wrong. Watch Now {"LSQLeadFields":[{"Seq":1,"Name":"First...

The one thing these 6 global crypto hubs all have in common…

The one thing these 6 global crypto hubs all have in common…

As the blockchain and cryptocurrency industries scale globally, nations are no longer adopting a wait-and-see attitude; they’re actively competing for a slice of the pie. Governments are recognizing that Web3 is a revolutionary technology with...

Trusted Abroad, Blocked at Home: Why Americans Need a Passport for Proven Medicines

Trusted Abroad, Blocked at Home: Why Americans Need a Passport for Proven Medicines

What drugs does the Food and Drug Administration (FDA) block patients and doctors from accessing that Canadian patients and doctors can get? To address the question, we compared the contents of the American Drugs@FDA database and the Canadian Drug...

Deja Vu? Colorado’s Special Session Ends with Budget Tweaks, But Again No Long-Term AI Deal

Deja Vu? Colorado’s Special Session Ends with Budget Tweaks, But Again No Long-Term AI Deal

Last Thursday, Aug. 21, the Colorado General Assembly reconvened for its 2025 Extraordinary Session, mostly focused on addressing the $750‒$800 million state budget shortfall created by the federal government’s passage of the One Big Beautiful...

MSMEs driving Viksit Bharat: Strengthening India’s trade, technology, and innovation

MSMEs driving Viksit Bharat: Strengthening India’s trade, technology, and innovation

Powering Bharat’s Rise: MSMEs Set to Lead India’s Next Export BoomIndia stands at the threshold of a transformative era, where Micro, Small and Medium Enterprises (MSMEs) are driving the engine of economic growth and global competitiveness. With...

European Commission Approval Gives Blood Cancer Patients a New Cell Therapy Option

European Commission Approval Gives Blood Cancer Patients a New Cell Therapy Option

Stem cell transplants that are a standard treatment for certain blood cancers are out of reach for many patients. The procedure requires cells from a matched donor, but a match isn’t always available. A new cell therapy derived from umbilical cord...

Crypto Assets Reach $3.5 Trillion, Gain Momentum in Switzerland and Liechtenstein

Crypto Assets Reach $3.5 Trillion, Gain Momentum in Switzerland and Liechtenstein

Free Newsletter Get the hottest Fintech Switzerland News once a month in your Inbox Crypto assets have continued to gain importance over the past twelve months. Alongside notable price movements, the ecosystem in Switzerland and the Principality...

ExCellThera gains EC authorisation for Zemcelpro cell therapy

ExCellThera gains EC authorisation for Zemcelpro cell therapy

ExCellThera has announced that the European Commission (EC) has granted conditional marketing authorisation for its Zemcelpro cell therapy to treat blood cancer patients without access to suitable donor cells. The approval was granted to the...

Afghan and international organisations reiterate their call for an accountability mechanism in Afghanistan

Afghan and international organisations reiterate their call for an accountability mechanism in Afghanistan

Open Letter To: Permanent Representatives of Member and Observer States of the United Nations Human Rights Council Dear Excellencies, We, the undersigned Afghan and international civil society organisations, write to you, once again, to share our...

Swiss VC Funding Surges, Driven by Biotech, ICT and Fintech

Swiss VC Funding Surges, Driven by Biotech, ICT and Fintech

Free Newsletter Get the hottest Fintech Switzerland News once a month in your Inbox Venture capital (VC) funding in Switzerland is rebounding this year, driven by large deals in biotech, information and communications technology (ICT), and...

Vaduz vs AZ Alkmaar Prediction and Betting Tips | August 14th 2025 

Vaduz vs AZ Alkmaar Prediction and Betting Tips | August 14th 2025 

Vaduz and AZ Alkmaar will trade tackles in the second leg of their UEFA Conference League third-round qualification tie on Thursday (August 14th). The game will be played at Rheinpark Stadion. The visitors hold a comfortable lead in the tie,...

IAEA chief says Iran’s co-operation with inspectors ’work in progress’

IAEA chief says Iran’s co-operation with inspectors ’work in progress’

Breadcrumb Trail Links World Author of the article: Associated Press Matthew Lee, Farnoush Amiri And Stephanie Liechtenstein Published Aug 27, 2025 • 5 minute read This handout satellite picture taken and provided by Maxar Technologies taken on...

10 reasons India sees Trump tariff crisis as an opportunity and a time to reboot

10 reasons India sees Trump tariff crisis as an opportunity and a time to reboot

In India, there is a view that US President Donald Trump’s 50 per cent tariffs are more of an opportunity for a reboot than a setback. Such a view is backed by the Indian economy’s fundamentals and historical trends. Independence analyses have...

Premier Says Foreign Investment Welcome

Premier Says Foreign Investment Welcome

Foreign investment is welcome in Slovakia, and every investor can count on assistance from the relevant ministries and specialised state agencies, said Prime Minister Robert Fico (Smer-SD) on Tuesday during the official opening of a new plant for...

EU Approves Twice-Yearly Yeytuo (Lenacapavir) for HIV Prevention

EU Approves Twice-Yearly Yeytuo (Lenacapavir) for HIV Prevention

The European Commission (EC) has granted marketing authorization to Gilead Sciences for Yeytuo (lenacapavir), making it the first and only twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) option approved in the European Union, as well...

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions